申请人:Chamoin Sylvie
公开号:US20100075966A1
公开(公告)日:2010-03-25
The invention relates to dihydroimidazoles of formula rac-(I),
wherein the radicals and symbols are as defined herein; their use as inhibitors of the interaction of the MDM2 protein with a p53-like peptide, new pharmaceutical formulations comprising said compounds, said compounds for use in the therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of proliferative diseases or for the manufacture of pharmaceutical formulations useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide, a pharmaceutical formulation e.g. useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide comprising said compound, methods of treatment comprising administration of said compounds to a warm-blooded animal, and/or processes for the manufacture of said compounds.
该发明涉及式rac-(I)的二氢咪唑,其中基团和符号如本文所定义;它们作为MDM2蛋白与类p53肽的相互作用抑制剂的用途,包括所述化合物的新药物配方,所述化合物用于治疗温血动物,特别是人类,它们用于治疗增殖性疾病或用于制造对MDM2蛋白与类p53肽相互作用调节有响应的药物配方,例如用于治疗对MDM2蛋白与类p53肽相互作用调节有响应的增殖性疾病的药物配方,包括所述化合物,包括所述化合物的治疗方法,包括将所述化合物用于温血动物的给药,和/或所述化合物的制造方法。